Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21098369 | 0.94 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL13211944 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL6571604 | 0.88 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL4770380 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL5257694 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL16359671 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL95881 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL1775216 | 0.88 | SMN1; SMN2 (0.82) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL13766445 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL13762099 | 0.86 | MEN1 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576120-B2 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-08-18 | — | — | US | disclosed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1720544-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005089747-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | SMN1; SMN2 855/4885NPC1 2317/4885POLB 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.